Gamma Knife Use for Non-Invasive Therapy in Brain Tumor Treatment: A Literature Review
Main Article Content
Abstract
Background: Gamma knife radiosurgery (GKRS) is a method of stereotactic radiosurgery (SRS) therapy that used in medical therapy for benign or malignancy brain tumor patient. The aim of this article is to know efectivity of GKRS method for brain tumor therapy based on new study that focused on therapeutic advantages, type of tumor, factors that influence therapy, side effect of therapy, complication, and new study of GKRS therapy.
Methods: This study is a narative literature review that be formed based on PRISMA-P guideline in 2015 through stages collecting, analysis, and citation of related journal. Colleted journal article was founded from PubMed with the topics are gamma knife, treatment, and brain tumor that include with the topics based on publication year, language, title, and abstract.
Discussion: Based on the results of the analysis, GKRS is SRS therapy that common used for patient with primary brain tumor or brain metastasis. GKRS therapy for patient with brain metastasis can decrease the risk of radionecrosis (RN) than whole brain radiotherapy (WBRT). The use of GKRS most often causes several symptoms after actions such as perilesional oedema, syncope, and anxiety. New study showed there are therapy combination between SRS and WBRT such as intensity-modulated radiation therapy (IMRT) that increasead efectivity of therapy for patient with brain tumor.
Conclusion: GKRS therapy showed that overall this therapy is effectiveness and recommended as non-invasive therapy for patient with primary brain tumor or brain metastasis.
Keywords: Gamma Knife, Therapy, Non-Invasive, Tumor, Brain
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
2. Zhang W, Jiang J, He Y, Li X, Yin S, Chen F, et al. Association between vitamins and risk of brain tumors: A systematic review and dose-response meta-analysis of observational studies. Front Nutr. 2022;9.
3. Kishi N, Nakamura M, Hirashima H, Mukumoto N, Takehana K, Uto M, et al. Validation of the clinical applicability of knowledge-based planning models in single-isocenter volumetric-modulated arc therapy for multiple brain metastases. J Appl Clin Med Phys. 2020;21(10):141–50.
4. Chen J, Sinclair G, Rozati H, Hill L, Pakzad-Shahabi L, Wang J, et al. Improving on whole-brain radiotherapy in patients with large brain metastases: A planning study to support the AROMA clinical trial. Radiother Oncol [Internet]. 2022;170:176–83. Available from: https://doi.org/10.1016/j.radonc.2022.02.011
5. Feuvret L, Vinchon S, Martin V, Lamproglou I, Halley A, Calugaru V, et al. Stereotactic radiotherapy for large solitary brain metastases. Cancer Radiother J la Soc Fr Radiother Oncol. 2014 Mar;18(2):97–106.
6. Rahman M, Murad GJA, Bova F, Friedman WA, Mocco J. Stereotactic radiosurgery and the linear accelerator: Accelerating electrons in neurosurgery. Neurosurg Focus. 2009;27(3):23–8.
7. Noda S, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol. 2009 Jul;19(3):171–8.
8. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, et al. E-Cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011;2011.
9. Velnar T, Bosnjak R. Radiosurgical techniques for the treatment of brain neoplasms: A short review. World J Methodol. 2018;8(4):51–8.
10. Becker SJ, Lipson EJ, Jozsef G, Molitoris JK, Silverman JS, Presser J, et al. How many brain metastases can be treated with stereotactic radiosurgery before the radiation dose delivered to normal brain tissue rivals that associated with standard whole brain radiotherapy? J Appl Clin Med Phys. 2023;
11. Tyagi A, Wu SY, Watabe K. Metabolism in the progression and metastasis of brain tumors. Cancer Lett. 2022;539.
12. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406.
13. Neth B, Carabenciov I, Ruff M, Johnson D. Temporal Trends in Glioblastoma Survival Progress then Plateau. Neurologist [Internet]. 2021 [cited 2023 Jun 19]; Available from: https://journals.lww.com/theneurologist/Fulltext/2022/05000/Temporal_Trends_in_Glioblastoma_Survival__Progress.6.aspx
14. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, et al. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: A retrospective analysis. Radiat Oncol. 2018;13(1):1–10.
15. Huff WX, Agrawal N, Shapiro S, Miller J, Kulwin C, Shah M, et al. Efficacy of pre-operative stereotactic radiosurgery followed by surgical resection and correlative radiobiological analysis for patients with 1-4 brain metastases: Study protocol for a phase II trial. Radiat Oncol. 2018;13(1):1–10.
16. Scorsetti M, Navarria P, Cozzi L, Clerici E, Bellu L, Franceschini D, et al. Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform. Radiat Oncol [Internet]. 2023;18(1):1–11. Available from: https://doi.org/10.1186/s13014-023-02216-5
17. Bodensohn R, Kaempfel AL, Fleischmann DF, Hadi I, Hofmaier J, Garny S, et al. Simultaneous stereotactic radiosurgery of multiple brain metastases using single-isocenter dynamic conformal arc therapy: A prospective monocentric registry trial. Strahlentherapie und Onkol. 2021;197(7):601–13.
18. Bachmann N, Leiser D, Ermis E, Vulcu S, Schucht P, Raabe A, et al. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiat Oncol. 2019;14(1):1–14.
19. Winter JD, Moraes FY, Chung C, Coolens C. Detectability of radiation-induced changes in magnetic resonance biomarkers following stereotactic radiosurgery: A pilot study. PLoS One. 2018;13(11):1–14.
20. Westover KD, Travis Mendel J, Dan T, Kumar K, Gao A, Pulipparacharuv S, et al. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol. 2020;22(12):1831–9.
21. Wang Y, Wang X, Guan Y, Song Y, Zhuang H, Wang E. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol. Thorac Cancer. 2020;11(5):1361–4.
22. Das S, Faruqi S, Nordal R, Starreveld Y, Kelly J, Bowden G, et al. A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases. BMC Cancer [Internet]. 2022;22(1):1–8. Available from: https://doi.org/10.1186/s12885-022-10480-z
23. Ginzac A, Dupic G, Brun L, Molnar I, Casile M, Durando X, et al. Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial. BMC Cancer. 2021;21(1):1–8.